Monitor progress toward the FDA meeting in mid-2026 on DLB psychosis indication, which could serve as a near-term catalyst. While financials improved, no revenue is generated yet, and clinical advancement remains key to valuation.
Price Chart
Executive Summary
Cognition Therapeutics (CGTX) reported financial results for Q4 and full year 2025, showing reduced net loss of $23.5 million (vs. $34.0M in 2024) on lower R&D and G&A expenses. The company has $37.0M in cash and expects to fund operations through Q2 2027. The primary focus is advancing zervimesine (CT1812) into a registrational trial for DLB psychosis, with an FDA meeting expected by mid-2026.
Key Financial Metrics
Key Facts
- Net loss decreased to $23.5M in 2025 from $34.0M in 2024 due to lower R&D and G&A spending.
- Cash, cash equivalents, and restricted cash totaled $37.0M as of December 31, 2025, up from $25.0M in 2024.
- Company expects cash runway through Q2 2027.
- Completed enrollment in Phase 2 'START' trial in early Alzheimer’s; topline results expected in 2027.
- Planning mid-year 2026 meeting with FDA Division of Psychiatry to discuss registrational path for zervimesine in DLB psychosis.
Financial Impact
Reduced net loss by $10.5 million year-over-year; cash position increased by $12.0 million.
Risk Factors
- Clinical development risk for zervimesine in DLB and Alzheimer’s, with topline data from the START trial not expected until 2027.
- Dependence on regulatory alignment and future grant funding to sustain operations beyond Q2 2027.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262885 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $0.7010 $0.7188 | ▲ +2.54% | ▲ +3.06% | $0.7196 (+2.65%) |
Jun 4, 2026 20w ago | 8-K | $1.36 $1.29 | ▼ −5.15% | ▼ −2.55% | $0.7196 (−47.09%) |
Jun 1, 2026 21w ago | Press Release | $1.25 $1.35 | ▲ +8.00% | ▲ +7.86% | $0.7196 (−42.43%) |
May 21, 2026 22w ago | Press Release | $1.25 $1.26 | ▲ +0.80% | ▲ +0.35% | $0.7196 (−42.43%) |
May 14, 2026 23w ago | Press Release | $1.20 $1.14 | ▼ −5.00% | ▼ −3.77% | $0.7196 (−40.03%) |
May 7, 2026 24w ago | 8-K | $1.21 $1.18 | ▼ −2.48% | ▼ −2.71% | $0.7196 (−40.53%) |
Apr 16, 2026 27w ago | Insider Cluster | $1.11 $1.19 | ▲ +7.21% | ▲ +5.99% | $0.7196 (−35.17%) |
Mar 26, 2026 30w ago | Press Release | $1.08 $0.7300 | ▼ −32.41% | ▼ −30.73% | $0.7196 (−33.37%) |
Mar 23, 2026 31w ago | Press Release | $1.13 $1.10 | ▼ −2.65% | ▼ −2.30% | $0.7196 (−36.32%) |
Mar 17, 2026 31w ago | Press Release | $1.15 $1.10 | ▼ −4.35% | ▼ −2.95% | $0.7196 (−37.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers